艾德生物(300685) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the third quarter was CNY 146,550,862.52, representing a year-on-year growth of 35.70%[8] - Net profit attributable to shareholders was CNY 30,693,961.74, up 16.72% year-on-year[8] - The company reported a net profit of CNY 43,895,500 for the third quarter, reflecting a year-on-year growth of 66.92%[8] - Total operating revenue grew by 32.84% to ¥412,461,054.84, attributed to increased product sales and effective market expansion[26] - The company’s net profit increased by 32.84% to ¥333,171,543.93, reflecting overall performance growth[26] - Total operating revenue for the current period reached ¥146,550,862.52, a 35.6% increase from ¥107,994,624.09 in the previous period[58] - Net profit for the current period was ¥30,693,961.74, representing a 16.3% increase compared to ¥26,297,189.54 in the previous period[61] - The company reported a total comprehensive income of ¥30,809,796.11, compared to ¥26,297,189.54 in the previous period[65] - The total comprehensive income for the period was ¥109,179,897.13, compared to ¥95,872,763.68 in the previous period[81] Earnings and Shareholder Returns - Basic earnings per share increased by 14.18% to CNY 0.2085[8] - Earnings per share (EPS) for the current period was ¥0.2085, compared to ¥0.1826 in the previous period, reflecting a 14.5% increase[65] - Basic and diluted earnings per share were both ¥0.7485, an increase from ¥0.6658 in the previous period[82] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was CNY 134,307,958.21, a significant increase of 79.59%[8] - Cash received from sales increased by 37.61% to ¥393,741,010.40, driven by higher sales revenue and collections[27] - The cash flow from operating activities generated a net amount of 134,307,958.21, compared to 74,784,959.85 in the previous period, marking an increase of about 79.7%[92] - The company received cash from operating activities totaling 420,323,498.84, compared to 299,710,930.80 in the previous period, reflecting an increase of approximately 40.2%[92] - The ending balance of cash and cash equivalents reached $238,084,352.43, up from $162,426,650.73, marking a growth of 46.5%[106] Assets and Liabilities - Total assets reached CNY 1,006,114,158.59, an increase of 22.88% compared to the end of the previous year[8] - Total assets increased to ¥1,006,114,158.59 from ¥818,746,842.78, representing a growth of approximately 22.9% year-over-year[47] - Current assets rose to ¥761,291,437.70 compared to ¥564,946,895.17, marking an increase of about 34.7%[41] - Total liabilities increased to ¥144,117,174.78 from ¥62,007,252.23, reflecting a growth of approximately 132.3%[44] - Current liabilities surged to ¥139,838,336.59 from ¥56,619,224.80, indicating an increase of around 147.5%[44] - The company's equity attributable to shareholders reached ¥861,996,983.81, up from ¥756,739,590.55, which is an increase of about 13.9%[47] Research and Development - Research and development expenses rose by 15.82% to ¥65,386,986.38, reflecting increased costs for R&D materials and personnel[26] - Research and development expenses totaled ¥65,386,986.38, up 15.5% from ¥56,456,579.63 in the previous period[76] Government Support and Other Income - The company received government subsidies amounting to CNY 14,532,733.51 during the reporting period[9] - Other income for the period was ¥14,532,733.51, compared to ¥10,909,473.61 in the previous period, reflecting a 33.5% increase[76] Shareholder Structure - The top ten shareholders held a combined 60.06% of the shares, with the largest shareholder owning 23.07%[13] - The company did not engage in any repurchase transactions during the reporting period[21] Taxation - The company reported a 199.94% increase in taxes payable, amounting to ¥10,285,640.85, due to higher corporate income tax provisions[26] - Tax expenses for the period were ¥19,841,977.36, an increase from ¥13,455,804.09 in the previous period[79] - The company incurred a tax expense of 17,942,000.59, compared to 12,888,897.39 in the previous period, which is an increase of about 39.5%[90]